Answers are grounded in this paper and cite their sources.
CDK4/6 inhibitors combined with endocrine therapy (ET) have become standard treatment for endocrine receptor (ER) positive, Her-2 negative metastatic breast cancer. Three agents, palbociclib, riboc...
No takes yet. Share an insight, caveat, or question.
Finnsdottir et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: